CD226 and breast cancer: In BC, CD226 was significantly downregulated on the surface of CD56+CD16 +NK cells and CD56+CD16-NK cells (46), and high genetic expression was associated with good prognosis in BC patients with stage II and III, as well as Luminal B (47).